Skip to main
OFIX
OFIX logo

Orthofix International (OFIX) Stock Forecast & Price Target

Orthofix International (OFIX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 62%
Buy 8%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

Orthofix Medical has raised its long-term net sales compound annual growth rate (CAGR) target to 6.5%-7.5%, reflecting a positive outlook for sustained growth in its core markets. The company reported adjusted EBITDA of $23.9 million for the latest quarter, representing a year-over-year increase and exceeding consensus expectations, alongside an adjusted EBITDA margin expansion. Additionally, significant growth in key segments was noted, with the Spine Fixation segment growing by 12% and the Bone Growth Therapies increasing by 9%, further supported by the anticipated FDA approval of AccelStim 2.0, indicating robust market potential.

Bears say

Orthofix Medical Inc. is facing a negative outlook primarily due to the recent discontinuation of its M6-C and M6-L artificial disc product lines, which are projected to result in a loss of $23.4 million in 2024 sales, thereby impacting EBITDA margins negatively. The company’s strategic shift towards spinal fixation and deformity correction, although aimed at addressing demand issues, has raised concerns regarding the integration risk associated with its merger with SeaSpine and the ability to maintain sales momentum amidst significant competition from better-financed rivals. Additionally, potential regulatory and legal challenges, along with evolving reimbursement rates in the U.S. healthcare landscape, pose considerable risks that could further hinder Orthofix's growth and profitability in the near future.

Orthofix International (OFIX) has been analyzed by 13 analysts, with a consensus rating of Buy. 62% of analysts recommend a Strong Buy, 8% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orthofix International (OFIX) Forecast

Analysts have given Orthofix International (OFIX) a Buy based on their latest research and market trends.

According to 13 analysts, Orthofix International (OFIX) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orthofix International (OFIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.